TheraKine and the Veterinary Market
An examination of pharmaceutical theory and practice within the
Veterinary Industry shows a major change in treatment therapies of
companion pets, professional and hobby animals such as equine (horses).
Until recently, common treatment choices were more often than not
limited to lesser-sophisticated over-the-counter medications. For
instance, if a dog or cat developed liver, heart, or some form of
cancer disease, it was a common course of treatment to let nature take
its course. Today, the Veterinary Pharmaceutical Industry is quite
different. Veterinary ophthalmology and equine ophthalmology have
become highly respected specialties.
The demographic data is compelling. In the US alone, over 71 million
households have a companion pet (There are roughly 74 million dogs and
91 million cats in the US). There are over 88,000 Veterinarians in the
US, over 600,000 worldwide and over 3,600 equine specialists. This
potential revenue stream has received the full attention of drug
manufactures. Most pharmaceutical companies now have separate,
well-organized divisions devoted to developing and promoting the use of
advanced veterinary medications. These treatments are often transferred
from the human side of medicine and reformulated for the weights and
sizes of animals. The medications will have already been trialed and
tested through various governing bodies for human use and expectations
of results are well documented, leading to easier efficacy.
TheraKine is following the precedent already set in the veterinary
industry and plans to make its pipeline of products available to
veterinary hospitals worldwide.